 |
|
|
| |
MGL-3196, a selective thyroid hormone receptor-beta agonist, significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study
|
| |
| |
Reported by Jules Levin
EASL 2018 Spril 13 Paris France
Oral session today
Stephen Harrison1 , Sam Moussa2 , Mustafa Bashir3 , Naim Alkhouri4 , Juan Frias5 , Seth Baum6 , Brent Tetri7 , Meena Bansal8 , Rebecca Taub9;
1Oxford University ; 2University of Arizona for Medical Sciences ; 3Duke University Medical Center ; 4 Texas Liver Institute, San Antonio, TX; 5University of California San Diego, Endocrinology, San Diego, United States ; 6Florida Atlantic University ; 7St Louis University School of Medicine ; 8Icahn School of Medicine at Mount Sinai ; 9Madrigal Pharmaceuticals
|
| |
|
|
|
|
|
